• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Quanterix Corp.

Quanterix wins FDA breakthrough nod for neurofilament light chain plasma test

April 22, 2022 By Sean Whooley

Quanterix (Nasdaq:QTRX) announced today that it received FDA breakthrough device designation for a multiple sclerosis (MS) diagnostic. Billerica, Massachusetts-based Quanterix designed its Simoa neurofilament light chain (NfL) plasma test as a prognostic aid in assessing the risk of disease activity in patients diagnosed with relapsing-remitting MS (RRMS). According to a news release, the company designed […]

Filed Under: Diagnostics, Digital Health, Featured, Food & Drug Administration (FDA), Genomics/Molecular Diagnostics, Health Technology, News Well, Regulatory/Compliance, Software / IT Tagged With: FDA, Quanterix Corp.

Quanterix appoints chief operating officer

November 19, 2020 By Danielle Kirsh

Quanterix (NSDQ:QTRX) this week said it appointed William Geist as chief operating officer, effective Nov. 16. Geist has more than 25 years of experience and most recently served as VP and general manager for Thermo Fisher Scientific’s protein and cell analysis and qPCR business units. He also held numerous sales, marketing and business development leadership roles […]

Filed Under: Business/Financial News, Neurological Tagged With: Quanterix Corp.

NIH announces more than $98M in contracts for new COVID-19 testing tech

October 7, 2020 By Chris Newmarker

The National Institutes of Health today announced six new contracts worth $98.35 million for COVID-19 testing approaches to improve sample collection, processing and results. NIH awarded the contracts in collaboration with the Biomedical Advanced Research and Development Authority (BARDA) as part of the Rapid Acceleration of Diagnostics (RADx) initiative. They cover innovations including integration with […]

Filed Under: Business/Financial News, Diagnostics, Digital Health, Featured, Funding Roundup Tagged With: coronavirus, COVID-19, Ellume, Flambeau Diagnostics, Luminostics, NIH, Quanterix Corp., U.S. Biomedical Advanced Research and Development Authority (BARDA), Ubiquitome, Visby Medical

Quanterix, Abbott sign licensing agreement

October 6, 2020 By Sean Whooley

Quanterix announced (NSDQ:QTRX) announced that it entered into a licensing agreement with Abbott (NYSE:ABT). Billerica, Mass.-based Quanterix’s agreement with Abbott is a non-exclusive, royalty-bearing license agreement that grants Abbott access to Quanterix’s portfolio of bead-based technology patents for use with in vitro diagnostic applications, according to a news release. Under the terms of the agreement, Quanterix will […]

Filed Under: Business/Financial News, Diagnostics Tagged With: Abbott, Quanterix Corp.

Quanterix prices $84.8M public offering

August 7, 2020 By Sean Whooley

Quanterix announced (NSDQ:QTRX) announced that it priced its previously announced underwritten public offering of common stock at $32 per share. Billerica, Mass.-based Quanterix is selling 2,651,108 shares of its common stock and expects to collect gross proceeds of approximately $84.8 million. Quanterix also granted underwriters a 30-day option to purchase up to 397,666 additional shares […]

Filed Under: Business/Financial News, Digital Health, Funding Roundup, Health Technology, Software / IT, Wall Street Beat Tagged With: Quanterix Corp.

Quanterix prices IPO common stock at $60m

August 9, 2019 By Danielle Kirsh

Quanterix today announced an initial public offering of nearly 2.4 million shares of common stock at $25.25 apiece for which it expects to gross $60 million. Billerica, Mass.-based Quanterix is developing a digital approach to immunoassays to allow single molecules to be counted. Its technology is used in the therapeutic areas of oncology, neurology, cardiology, […]

Filed Under: Initial Public Offering (IPO), Wall Street Beat Tagged With: Quanterix Corp.

Ex-Millipore CEO Madaus steps down from Covidien board

February 7, 2014 By Chris Walker Leave a Comment

Ex-Millipore CEO Madaus steps down from Covidien board

Covidien (NYSE:COV) said Dr. Martin Madaus will step down from its board of directors to take an open CEO position with a privately-owned company.

Filed Under: News Well Tagged With: Covidien, Merck Millipore, Personnel Moves, Quanterix Corp., Roche

Covidien taps Quanterix CEO for board | Personnel Moves

November 27, 2011 By MassDevice staff Leave a Comment

Med-tech titan Covidien (NYSE:COV) named Quanterix Corp. CEO Martin Madaus to its board of directors.

Madaus, the former head of Millipore, was tapped by Quanterix in September for the corner office. His nomination, effective Dec. 1, is slated for a shareholder vote next year.

Filed Under: News Well Tagged With: BeneChill Inc., Boston Scientific, Covidien, Dune Medical Devices Inc., Personnel Moves, Quanterix Corp., Regeneron, Viking Systems Inc.

Intrinsic Therapeutics puts a new man in charge | Personnel Moves

September 22, 2011 By MassDevice staff Leave a Comment

Intrinsic Therapeutics

Intrinsic Therapeutics named Wright Medical (NSQD:WMGI) veteran Cary Hagan as its new President & CEO. Greg Lambrect, founder of Intrinsic will stay on as executive director.

"Cary’s proven success in bringing new technologies to the global market makes him an ideal choice to lead Intrinsic’s next stage of growth as we expand our international clinical and commercial activity," said Lambrecht in prepared remarks.

Filed Under: News Well Tagged With: AdvaMed, CardioDx Inc., General Electric, Hanger Inc., Personnel Moves, PPD Inc., Quanterix Corp., SANUWAVE Health Inc., Securities & Exchange Commission (SEC), Vicor Corp.

Dr. Martin Madaus joins Quanterix as CEO

September 21, 2011 By MassDevice Contributors Network Leave a Comment

Former CEO of Millipore Brings Extensive Commercial Expertise to New Role

Filed Under: Uncategorized Tagged With: Personnel Moves, Quanterix Corp.

Tissue Genesis starts trial on vascular grafts with fat-derived stem cells | Research roundup

April 20, 2011 By MassDevice staff Leave a Comment

Clinical trials roundup

Tissue Genesis Inc. began clinical trials for a peripheral vascular disease (PVD) treatment composed of adipose-derived adult stem cell-coated vascular grafts. Adipose is more commonly know as fat, a tissue that the company believes has high-output regenerative medicine potential.

The Honolulu-based Tissue Genesis is the first to initiate an FDA-approved trial using the patient’s own fat-derived adult stem cells (ASCs) prepared at the point-of-care, according the company company.

Filed Under: News Well, Stem Cells Tagged With: Bone Solutions Inc., Clinical Trials, ConvaTec, Quanterix Corp., Tissue Genesis Inc.

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy